Health Canada22 Jul 2026
DCA Vantage® HbA1c (DX Claim)
Health Canada published a recall notice for DCA Vantage® HbA1c (DX Claim) on 22 Jul 2026. It is one of 311 notices of this kind from Health Canada since 2 Apr 2026 in AreaZine's record.
Recall
The recall notice
- Issued by
- Health Canada
- Issued
- 22 Jul 2026
- Recall type
- Health product recall
- Companies
- Siemens Healthcare Diagnostics Inc.511 Benedict Ave, Tarrytown, New York, United States, 10591
- Official source
- Health Canada: the notice at its source
The latest from Health CanadaEvery warning and recall in Canada
Source: Health Canada: the notice at its source. AreaZine rebuilds this page from the agency's record; the agency's page is the one to act on. Contains information licensed under the Open Government Licence – Canada.
The notice as issued
Issue: Siemens Healthineers has confirmed through customer complaint investigation and internal testing that delamination of the buffer pull-tab may occur in a small subset of cartridges. Delamination occurs when bonded material layers within the pull-tab separate, preventing full release of the buffer solution into the reaction chamber and reducing the reagent volume available for analysis.When delamination occurs, it may result in falsely low (negatively biased) HbA1c results or instrument-generated error codes that prevent completion of the test. The issue observed in approximately 0.07-0.5% of cartridges in these lots. The majority of the cartridges in these lots continue to perform as intended. Additional information Details Original published date: 2026-07-22 Affected products: Affected products Lot or serial number Model or catalogue number DCA Vantage® HbA1c (DX Claim) 0916065 10698915 Issue
Source: Health Canada: the notice at its source. The text is the agency's, unedited. Contains information licensed under the Open Government Licence – Canada.